Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 5,402 Shares

Key Points

• Houte Hans Van, CFO of Nurix Therapeutics, sold 5,402 shares at an average price of $11.03, resulting in a total transaction of approximately $59,584 and a 13.20% decrease in his overall position in the company.
• Nurix Therapeutics reported a quarterly EPS of ($0.52), exceeding analysts’ expectations of ($0.79), with revenues significantly surpassing estimates at $44.056 billion for the quarter.
• Analyst ratings for NRIX show a consensus of “Moderate Buy” with a range of price targets, including Wells Fargo’s reduction from $32.00 to $25.00 and Stephens maintaining a target of $30.00.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 5,402 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $11.03, for a total transaction of $59,584.06. Following the transaction, the chief financial officer owned 35,512 shares in the company, valued at $391,697.36. This represents a 13.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Houte Hans Van also recently made the following trade(s):

• On Wednesday, July 30th, Houte Hans Van sold 4,304 shares of Nurix Therapeutics stock. The stock was sold at an average price of $12.01, for a total transaction of $51,691.04.

Nurix Therapeutics Stock Up 1.3%

NRIX traded up $0.15 during trading on Tuesday, hitting $11.43. The company's stock had a trading volume of 126,434 shares, compared to its average volume of 879,829. The business's 50 day simple moving average is $11.85 and its 200-day simple moving average is $12.93. The firm has a market cap of $873.52 million, a PE ratio of -4.39 and a beta of 2.14. Nurix Therapeutics, Inc. has a one year low of $8.18 and a one year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.27. The firm had revenue of $44,056 billion during the quarter, compared to analysts' expectations of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. Equities research analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors have recently bought and sold shares of NRIX. GF Fund Management CO. LTD. purchased a new position in shares of Nurix Therapeutics in the 4th quarter worth $28,000. Aquatic Capital Management LLC purchased a new position in shares of Nurix Therapeutics in the 4th quarter worth $87,000. Summit Investment Advisors Inc. grew its stake in shares of Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after buying an additional 877 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Nurix Therapeutics in the 4th quarter worth $164,000. Finally, Exchange Traded Concepts LLC grew its stake in shares of Nurix Therapeutics by 38.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock worth $109,000 after buying an additional 2,562 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NRIX. Wall Street Zen upgraded shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. HC Wainwright dropped their target price on shares of Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, July 14th. Stephens reiterated an "overweight" rating and issued a $30.00 target price on shares of Nurix Therapeutics in a research note on Thursday, July 10th. Wells Fargo & Company dropped their target price on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 9th. Finally, Oppenheimer restated an "outperform" rating and set a $30.00 price objective (down previously from $32.00) on shares of Nurix Therapeutics in a research report on Thursday, July 31st. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $28.87.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.